Stockreport

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia [Yahoo! Finance]

Larimar Therapeutics, Inc.  (LRMR) 
PDF Nomlabofusp was selected based on potential for clinical benefit in a rare neurodegenerative disease and demonstrated development program readiness START pilot progra [Read more]